Drugs / UM171
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02668315 | Dec 2015 → Aug 2018 | hematopoietic and lymphoid cell neoplasm | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04103879 Background | Nov 2020 → Feb 2026 | hematopoietic and lymphoid cell neoplasm | ExCellThera inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UM171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04103879 ↗ |
| Action | Activate | “UM171, a haematopoietic stem cell self-renewal agonist” PMID 31704264 ↗ Nov 2019 |
| Modality | Small molecule | “UM171, a pyrimidoindole derivative” PMID 39293082 ↗ Nov 2024 |